Search the Newsreel

Strata Critical Medical (SRTA) co-CEO receives PSU share awards

Crimson Tide plc Reports £0.2m Pre-Tax Profit in FY26 and Secures Record £3.9m Retail Contract

Crinetics Pharmaceuticals (NASDAQ:CRNX) Issues Earnings Results

Crinetics Pharmaceuticals (CRNX) Earnings Date and Reports 2026

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Tops Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to a loss of $1.23 per share a year ago. These figures are adjusted for non-recurring items. This …

Dow, S&P 500, Nasdaq Futures Climb As Markets Gear Up For Another Key Earnings Week: USO, PLTR, CRML, IONQ Stocks In Focus

Critical Resources' AU$3.2m Market Cap Fall Books Insider Losses

Strata Critical Medical Inc (SRTA) Q2 2026 Earnings Report Preview: What To Look For

Crizac Q1 Results: Net profit rises 1% YoY to ₹461.66 lakh

E.W. Scripps Company (The) (NASDAQ:SSP) Receives Average Recommendation of "Hold" from Brokerages

Is Neurocrine Biosciences (NBIX) A Bargain After Strong Q2 Results And Higher Guidance?

Neurocrine Biosciences (NBIX) reported strong Q2 2026 results and raised full-year INGREZZA sales guidance, yet its share price declined by about 10% on the day of the announcement, despite positive longer-term momentum. The stock is currently valued at $166.80, considered 13.5% undervalued by Simply …

Earnings Flash (TIDE.L) Crimson Tide PLC Reports FY26 Revenue GBP5.9M

CRISPR Therapeutics (CRSP) Expected to Release Earnings on Monday

CRISPR Therapeutics (CRSP) is anticipated to release its Q2 2026 earnings on Monday, August 10th, with analysts forecasting a loss of $1.20 per share and revenue of $7.45 million. The company's shares are currently trading near their 52-week low, and it remains unprofitable, though …

Empowered Funds LLC Acquires New Shares in Carter's, Inc. $CRI

Empowered Funds LLC has acquired 136,908 shares of Carter's, Inc. (NYSE:CRI) during the first quarter, valuing their new position at approximately $4.9 million. This acquisition comes as Carter's reported strong second-quarter earnings, beating analyst estimates, but issued third-quarter revenue guidance below expectations. Analysts currently …

Carter's, Inc. $CRI Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP significantly increased its stake in Carter's, Inc. (NYSE:CRI) by 36.6% in the first quarter, now owning 4.79% of the company. This comes as Carter's reported strong second-quarter earnings, beating analyst estimates for both EPS and revenue, though third-quarter revenue guidance …

Acrivon Therapeutics (ACRV) Dips 1.3% to $1.50 as Biotech Volatility Continues - Shakeout Pattern

CRCT Q1 2026 Earnings: EPS Smashes Estimates by 145.1% as Shares Edge Higher - Earnings Whisper Number

Critical Minerals Group Reaches Pre-Feasibility Milestone at Lindfield Vanadium Project

Did Strong Q2 Results and Tariff Windfall Just Shift Carter’s (CRI) Investment Narrative?

Carter's, Inc. reported past second-quarter 2026 results with net sales rising to US$615.49 million and net income jumping to US$104.96 million, alongside a tariff recovery that left it holding more than US$650 million in cash. Despite tightening its full-year outlook to a modest 2%–3% …

CRISPR Therapeutics (CRSP) Rebounded In Its Latest Session, Is It Still Well Below Fair Value?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. CRISPR Therapeutics Stock Reaction To Recent Trading Session CRISPR Therapeutics (NasdaqGM:CRSP) recently finished a trading session with a positive price move that outpaced the S&P …

Neurocrine Biosciences (NBIX) Is Down 5.1% After Q2 Earnings Beat And Higher INGREZZA Guidance – What's Changed

In the second quarter of 2026, Neurocrine Biosciences reported revenue of US$959.0 million and net income of US$144.4 million, sharply higher than a year earlier and ahead of analyst expectations, with INGREZZA, CRENESSITY, and newly acquired VYKAT XR leading record sales. The company also …

Neurocrine Biosciences (NBIX) Appoints Four Senior Leaders As Pipeline And Portfolio Expand

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Neurocrine Biosciences appointed a new Chief Business Officer and three Senior Vice Presidents to its senior leadership team. The moves come as the company …

Scripps completes acquisition of WTVQ in Lexington

CINCINNATI, Aug. 01, 2026 (GLOBE NEWSWIRE) -- The E.W. Scripps Company (NASDAQ: SSP) has completed its previously announced acquisition of WTVQ, the ABC affiliate in Lexington, Kentucky, from Morris Network, Inc. for $15.8 million. The acquisition creates a duopoly in Lexington with Scripps’ existing …

Is Carter's (CRI) Undervalued On Its Earnings Update And New Guidance?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Carter's (CRI) is back in focus after reporting its second quarter and first half 2026 results, alongside fresh guidance for the rest of …

CRSP Stock Price and Chart — NASDAQ:CRSP

This page provides a comprehensive overview of CRISPR Therapeutics AG (CRSP) stock, including its current price, historical performance, key financial statistics, and company details. It also features a collection of recent news and trading ideas from analysts and community members regarding CRSP's stock movement, …

CRCT Q1 2026 Earnings: EPS of $0.10 Delivers 145% Upside Surprise - Estimate Accuracy

Neurocrine Biosciences (NBIX) Stock Slides As Growth Spending Steals Focus

Neurocrine Biosciences (NBIX) stock dropped 10% despite strong Q2 2026 revenue and earnings, indicating the market is reacting to growth spending rather than current earnings. The company showed robust performance with INGREZZA and emerging products like CRENESSITY and VYKAT XR, but analysts are cautious …

E.W. Scripps (NASDAQ:SSP) Rating Increased to Hold at Wall Street Zen

Neurocrine Biosciences (NBIX) Lifts INGREZZA Guidance, Is The Pullback A Bargain?

Critical Minerals Stocks Riding The Tungsten Discovery Theme

Neurocrine Biosciences, Inc. Revenue Breakdown – NASDAQ:NBIX

Neurocrine Biosciences, Inc. (BX:NB3) reported a total revenue of 2.27 billion CHF last year, primarily driven by its Pharmaceuticals segment. The majority of this revenue, also 2.27 billion CHF, came from operations within the United States. This indicates a strong reliance on the pharmaceutical …

Neurocrine Biosciences (NBIX) Is Down 5.2% After Earnings Beat And Raised INGREZZA Outlook Has The Bull Case Changed?

Neurocrine Biosciences reported strong Q2 2026 earnings with revenue of US$959.0 million and net income of US$144.4 million, and raised its INGREZZA sales guidance. Despite these positive results, the stock fell 5.2%, reflecting ongoing concerns about pricing pressure and product concentration risks within its …

Neurocrine Biosciences Q2 Earnings Call Highlights

Neurocrine Biosciences reported strong Q2 2026 revenues exceeding $950 million, a nearly 40% year-over-year increase, driven by INGREZZA and CRENESSITY sales, plus VYKAT XR's partial contribution. The company raised its full-year INGREZZA sales guidance and is integrating VYKAT XR following a $2.9 billion acquisition. …

3 Stocks Under $10 We Think Twice About

3 Stocks Under $10 We Think Twice About Investors can certainly boost their returns by concentrating on stocks trading between $1 and $10. However, a disciplined approach is necessary because many of these businesses are speculative and lack the underlying fundamentals to support their …

CARTERS INC 2026: Revenue $615.49M, EPS $2.87— 10-Q Summary

CARTERS INC (CRI) reported strong financial results for the quarter ended 2026, with revenue reaching $615.49M and diluted EPS of $2.87. This growth was attributed to increased average unit retail and volume across all channels, leading to a significant rise in net income to …

Criteo amends revolving credit facility, seeks 364-day maturity extension

Criteo has amended its multicurrency revolving facility agreement, allowing it to resign as a borrower following its planned redomiciliation while remaining a guarantor. The amendment also allows a future U.S.-domiciled successor to join as a borrower under certain conditions. Additionally, Criteo has requested a …